Figure 1.

Strategies for dual antiplatelet therapy after PCI. The majority of patients undergoing percutaneous coronary intervention (PCI) should be treated with guideline recommended dual antiplatelet therapy (DAPT) (clopidogrel in elective PCI and ticagrelor or prasugrel in patients with acute coronary syndrome (ACS)). In elective PCI patients, an escalation strategy can be considered in some situations, when the thrombotic risk is higher than the bleeding risk. In ACS patients, de-escalation can be considered when the bleeding risk is higher than the thrombotic risk or for socio-economic considerations.